About Biopsin
Biopsin is a company based in Singapore (Singapore) founded in 2018 by Amit Kumar and Sheetal Sinha. Biopsin has raised $175 thousand across 1 funding round from investors including HAX and Entrepreneur First. Biopsin operates in a competitive market with competitors including AFYREN, Spore Biotechnologies, Mesosil, Celsis and Source Molecular, among others.
- Headquarter Singapore, Singapore
- Founders Amit Kumar, Sheetal Sinha
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biopsin Pte Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$175 K (USD)
in 1 rounds
-
Latest Funding Round
$175 K (USD), Seed
Jan 23, 2019
-
Investors
HAX
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biopsin
Biopsin has successfully raised a total of $175K through 1 strategic funding round. The most recent funding activity was a Seed round of $175 thousand completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biopsin
Biopsin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include HAX and Entrepreneur First.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startups are accelerated via a 111-day program with seed funding.
|
Locked | Locked | Locked | |
|
Provider of a program turning individuals into funded technology company founders
|
Locked | Locked | Locked |
Investor details for Biopsin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biopsin
Investment portfolio details for Biopsin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biopsin
Detailed financials for Biopsin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biopsin Comparisons
Peer comparison for Biopsin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biopsin
Biopsin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AFYREN, Spore Biotechnologies, Mesosil, Celsis and Source Molecular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
|
| Locked | Locked | Locked |
Microbial detection technology is developed for life science industries.
|
|
| Locked | Locked | Locked |
Antimicrobial materials are developed for infection prevention in medical devices.
|
|
| Locked | Locked | Locked |
Rapid microbial screening systems are manufactured for quality control testing.
|
|
| Locked | Locked | Locked |
Technology for microbial source tracking is provided by Source Molecular.
|
Detailed competitors of Biopsin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biopsin
Complete news archive for Biopsin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biopsin
Biopsin was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Biopsin is headquartered in Singapore, Singapore.
Amit Kumar is the current CEO of Biopsin. They have also founded this company.
Biopsin is a funded company, having raised a total of $175K across 1 funding round to date.
Biopsin was founded in 2018 in Singapore and operates in the biotechnology sector. A microbial detection system is provided for analyzing food, beverages, water, consumer goods, and pharmaceuticals. Pathogenic microbes are extracted and trapped from samples, followed by quantitative analysis at the single-cell level. Operations are focused on real-time testing to ensure product safety across these industries.
Biopsin's top competitors include AFYREN, Spore Biotechnologies and NCIMB.
Biopsin has 2 investors. Key investors include HAX, and Entrepreneur First.